Cargando…
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
BACKGROUND: In two clinical trials of the vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib in advanced renal cell carcinoma (mRCC), we found interleukin-6 as predictive of pazopanib benefit. We evaluated the prognostic significance of candidate cytokines and angiogenic factors...
Autores principales: | Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558688/ https://www.ncbi.nlm.nih.gov/pubmed/28683470 http://dx.doi.org/10.1038/bjc.2017.206 |
Ejemplares similares
-
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012) -
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015) -
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
por: Hamaoka, T, et al.
Publicado: (2010) -
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
por: Pinato, D J, et al.
Publicado: (2014) -
Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases
por: Kahlert, C, et al.
Publicado: (2014)